The US Food and Drug Administration (FDA) has cleared Prodeon Medical’s implantable technology for treating lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). The ...

TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...

Among middle-aged and older men, a higher percentage of total food weight from ultraprocessed food (UPF) is associated with a ...

GREENBRAE, Calif.--(BUSINESS WIRE)--MarinHealth Medical Center (MHMC) announced today that its surgeons have performed the first Aquablation procedures to treat benign prostatic hyperplasia (BPH).

Modern medical research shows that drug and surgical treatments for benign prostatic hyperplasia and chronic prostatitis carry high risks, while Dr Allen's Device, developed by Fine Treatment, an ...

TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...

Profound Medical Corp. (NASDAQ:PROF) is one of the best Canadian stocks with huge upside potential. On June 10, Profound Medical announced the successful completion of the first commercial benign ...

Profound Medical (PROF) announced the upcoming launch of its TULSA-AI Volume Reduction module for optimizing the treatment of patients with benign prostatic hyperplasia, or enlarged prostate, at the ...

Benign prostatic hyperplasia (BPH) is associated with elevated risks for depression and anxiety, with a causal link to depression supported by genetic evidence, according to a study published online ...